ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sparsentan

Also written as “Sparsentan”, “PS433540” and “RE-021 (Sparsentan)”.

Its studies are mostly in Glomerulosclerosis, Focal Segmental · Glomerulonephritis, IGA · Hypertension · Proteinuria, led by 2 companies.

Drug pageSparsentan: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 9, 20259 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Travere Therapeuticsits history only72 open or runningphase 4since Oct 9, 2025Jun 4, 2012Mar 2027phase 4 · NCT07219121
Ligand Pharmaceuticals20 open or runningphase 2since Aug 29, 2007Aug 29, 2007none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Ligand Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 29, 2007First study: phase 2 study in HypertensionFirst studyNCT00522925 · 280 enrolled · United States
  2. Mar 6, 2008Phase 2 study in HypertensionNCT00635232 · 261 enrolled · United States
  3. Jun 9, 2015Named sparsentanINNProposed as its International Nonproprietary Name in WHO's List 113 · before, PS433540

TargetBeta

AGTR1 →EDNRA →read by rule
“Endothelin receptor ET-A antagonist; Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule

Studies

All 2 Ligand Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00635232Hypertension · United States2CompletedNov 2008261
NCT00522925Hypertension · United States2CompletedApr 2008280

How it is read

Names in the registry

  • “Sparsentan”, 5 entries
  • “PS433540”, 5 entries
  • “sparsentan”, 2 entries
  • “RE-021 (Sparsentan)”, 1 entry
  • “RE-021, sparsentan”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.